EGFR and non-small cell lung carcinoma: Both are orally active, selective EGFR tyrosine kinase inhibitors (EGFR-TKI) that demonstrated anti-tumoural activity in approximately 10% of unselected NSCLC (Fukuoka et al, 2003; Kris et al, 2003), with a survival benefit when compared with placebo that was statistically significant only in the case of erlotinib (Shepherd et al, 2005; Thatcher et al, 2005).